Puma Biotechnology (PBYI) PT Lowered to $87 at Stifel

Stifel lowered its price target on Puma Biotechnology (NASDAQ: PBYI) to $87.00 (from $95.00) while maintaining a Buy rating.

Analyst Alex Schwartz commented, "Yesterday Puma reported 1Q18 numbers that included $66.5 million in revenue and a $24.3 million net loss. Nerlynx revenues of $36.0 million were below our $42.1 million estimates but in-line with $36 million consensus estimates. As part of the release, management indicated they now expect NALA data during 4Q18/2019 (versus prior 2Q18 expectations) due to slower than expected event rate. As a result, we are pushing out our metastatic revenue estimates by a year. Accordingly, our target price decreases from $95 to $87. Despite our reduction in target price, we remain positive on the stock due to a reasonable chance at positive metastatic breast cancer data (NCCN already recommends Nerlynx to BC patients with brain metastases) and Nerlynx extended adjuvant EMA re-examination success."

You May Also Be Interested In

• Barclays Upgrades Poste Italiane SpA (PST:IM) (PITAF) to Overweight
• Axis Capital Limited Downgrades Tech Mahindra Ltd. (TECHM:IN) to Sell (4)
• Axis Capital Limited Upgrades LTM Ltd (LTM:IN) to Buy (1)